Table 4 The R_pred/obs ratios for PK parameters of Nicardipine in healthy and diseased populations.

Dose	C_max (ng/mL)			AUC_0–∞ (ng/mL.hr)			CL (L/h)			References
Dose	O.V.	P.V.	R Ratio	O.V.	P.V.	R Ratio	O.V.	P.V.	R Ratio	References
IV administration in healthy individuals
210 ug/kg for 30 min	230.14	226.37	0.984	220.4	227.17	1.031	66.7	64.45	0.966	³⁸
0.16 mg/kg	424.69	511.05	1.203	217.84	203.58	0.934	51.41	55.01	1.07	³³
5 mg/hr for 3 h	123.3	105.44	0.855	447.32	360.76	0.806	33.53	41.58	1.24	³⁴
0.885 mg	8.69	6.65	0.765	12.62	11.27	0.893	70.13	78.56	1.12	³⁵
1.05 mg	34.65	29.25	0.844	21.08	21.58	1.023	49.8	48.66	0.977	³⁶
5 mg	194.79	140.65	0.722	109.96	112.26	1.021	45.47	44.54	0.979	³⁷
Oral administration in healthy individuals
30 mg	78.09	60.52	0.775	116.98	142.16	1.215	256.46	211.03	0.823	³⁴
40 mg	27.65	34.73	1.256	179.38	131.32	0.732	222.99	304.6	1.366	³⁶
30 mg	33.27	36.26	1.089	83.06	85.95	1.035	361.17	349.74	0.968	³⁹
30 mg	22.14	38.13	1.722	66.11	87.85	1.329	453.79	341.45	0.752	⁴⁰
20 mg	20.63	24.35	1.18	52.92	62.99	1.19	393.88	317.47	0.806	⁴¹
30 mg	31.48	37.95	1.206	101.03	97.53	0.965	296.95	307.6	1.036	⁴¹
20 mg	25.82	24.29	0.941	52.03	60.4	1.161	384.35	331.1	0.861	⁴²
Oral administration in CKD population
20 mg	33.04	27.25	0.825	86.09	75.19	0.872	232.22	266	1.15	⁴¹
30 mg	55.02	31.86	0.579	152.02	103.50	0.680	194.45	290.44	1.494	⁴¹
Oral administration in LC population
30 mg	67.12	74.45	1.109	307.21	173	0.563	97.65	173.41	1.775	³⁹

C_max maximal plasma concentration, AUC_0–∞ area underneath the curve from time zero to infinity, CL clearance, CKD chronic kidney disease, LC liver cirrhosis, IV intravenous, O.V. the observed parameter value, P.V. the predicted parameter value, R Ratio P.V./O.V.

Quick links

Search